



華美化學學會

Chinese American Chemical Society

2009 Tri-State CACS Annual Symposium

Innovation and Entrepreneurships in Pharmaceutical and Chemical R&D

Co-sponsored by
The Department of Medicinal Chemistry
Ernest Mario School of Pharmacy, Rutgers University

8:30 am – 4:30 pm
Saturday, June 13, 2009

Busch Campus Center
Rutgers University, Piscataway, NJ
604 Bartholomew Rd
Piscataway, NJ 08854

www.tristatecacs.org



Contents

Acknowledgment	3
Forward	4
Program Schedule	5
Symposium Logistics Contact	6
Abstracts & Speaker BioSketches	7
Tri-State CACS Officers	18



Acknowledgment

Tri-State CACS gratefully acknowledges the following sponsors for their support of Tri-State CACS and this symposium:

Department of Medicinal Chemistry
Ernest Mario School of Pharmacy, Rutgers University

Schering-Plough Research Institute
Schering-Plough Dollars for Volunteers Program

Johnson & Johnson

ExxonMobil Research & Engineering Co.
ExxonMobil VIP Fund

Dow Advanced Materials

Sanofi-aventis

Bristol-Myers Squibb

Merck & Co

Wyeth

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

ChemPartner

AstaTech

Acesys PharmTech

Millpore Corp

Mestrelab Research

Teledyne ISCO

Bruker Daltonics, Inc.

Thermo Fisher Scientific

Xenobiotic Laboratories

Primera Analytical solutions

Yamazan



Forward

Welcome to the 2009 Tri-State CACS Annual Symposium!

On behalf of the Tri-State CACS, we would like to express our sincere gratitude to our sponsors and to our volunteers for their support and contributions to the cause of our organization.

Over the past decade, pharmaceutical industry have gone through many changes and had its prospective years. However, despite steady demand for its products, the industry's current business model is both economically and operationally challenged. Meanwhile, the world is witnessing fast economic development in Asia, particularly in China. Therefore, the American chemical and pharmaceutical industries as a whole and the Chinese-American chemical professionals in particular, are presented with unprecedented challenges and opportunities in this rapid changing environment. After the successful Beijing International Pharmaceutical & Chemical Intellectual Property Forum and International Pharmaceutical R&D Forum, CACS has started a new mission to promote dialogues and collaborations in chemical and pharmaceutical R&D organizations between the US and China. This year's theme, "Innovation and Entrepreneurships in Pharmaceutical and Chemical R&D", continues on last years' theme and reflects some of the current industry trends in combating the economic downturn.

We are extremely excited to have a group of high-caliber R&D leaders from major chemical & pharmaceutical companies to share their visions and thoughts about the future growth drivers for our industries in the current environment. Among them are Dr. Gregory J. Szpunar, Senior Vice President of Pharmaceutical Sciences and Drug Metabolism of Schering-Plough Research Institute, Dr. Arthur A. Andrews, Vice President of Global Drug Product Development of Johnson & Johnson Pharmaceutical R&D, Dr. Paul Juniewicz, Senior Vice President & Head for Global External Innovation Access, sanofi-aventis, and Dr. Nilesh Shah, Research & Development Director, Household & Personal Care, Dow Advanced Materials. In addition, an introduction to ACS Diversity Partner Program will be presented by Dr. Guang Cao of Exxon Mobile with a focus on Asian chemical professionals. As always, entrepreneurs in smaller research and service business are well-presented in the symposium and for a second year, we will also feature a vendor show as well.

Enjoy the symposium.

For over a quarter of a century, CACS has continued to promote cohesion among Chinese-American chemical professionals, and to address their common interests and concerns. In addition to holding events like this, Tri-State CACS has continued Young Chemist Awards to help cultivate interests in chemical sciences among high school students. We also initiated a mentoring program to help junior colleagues gain a quick footing in their respective careers in the US.

Please join us as we face new challenges and new opportunities!

Xuhong Sunny Wang
President

Duxi Zhang, PhD
President-Elect

Longqin Hu
Immediate Past-President



Program Schedule

8:30 Registration / Breakfast & Coffee

Morning Session

(Session Chairs: Duxi Zhang & Jinquan Dong)

9:00 Opening Remarks

9:10 Dr. Gregory Szpunar, Senior VP, Pharmaceutical Sciences and Drug Metabolism of Schering-Plough Research Institute
"Big Pharma - Where is It All Going?"

9:50 Dr. Arthur Andrews, VP of Global Drug Product Development, Johnson & Johnson Pharmaceutical R&D
"Pharmaceutical Development: Understanding Major Industry Changes in How to "Design, Develop, & Deliver" New Drugs"

10:30 Coffee Break & Networking

10:50 Dr. Paul Juniewicz, VP & Global Head for Access to External Innovation, sanofi-aventis
"Changing Paradigms in Pharmaceutical R&D"

11:30 Dr. Nilesh Shah, Research & Development Director, Household and Personal Care, Dow Advanced Materials
"Provide Solutions in a Hyper-Competitive Marketplace"

12:10 Lunch

Afternoon Session

(Session Chairs: Fangbiao Li & Wendy Zhong)

1:20 Dr. Yuguang Wang, Senior VP of Integrated Services and Library Generation, ChemPartner
"Life in a CRO Company"

1:45 Dr. Guang Cao, ACS Diversity Program Asian Partner, Exxon Mobile Research & Engineering
"ACS Diversity Partner Program"

2:10 Dr. Zhe-ming Gu, VP & Head of Drug Metabolism and Biotransformation, XenoBiotic Laboratories
"Drug Metabolism in Drug Discovery & Development - Opportunities for CRO in China"

2:35 Dr. Hong Xu, VP of Business Development, Medicilon:
"Creating Innovative Models of Partnering with China to Enrich Pharmaceutical Product Pipelines"

3:00 Coffee Break and Networking

3:15 Matt Giovine, Senior Director of Business Development, AstaTech Inc.
"Technology Licensing Opportunity for Small CRO Companies"

3:40 Dr. Chen Peng, Director of Business Development, Mestrelab Research:
"From Chemistry to NMR Software Development to Business Development: My Experience"

4:05 Charles Ye, President & Founder, Acesys PharmaTech
"Acesys Approach to One-stop CRO Service-Drug Discovery Platform at China Medical City"

4:30 Closing Remarks



Vendor Show (all day event)
9:00AM – 4:00PM

(Session Chairs: Fanwen Zeng, Qingjie Ding, & Bin Wei)

Bruker Daltonics	http://www.bruker.com
Dionex	http://www.dionex.com
Mestrelab Research	http://www.mestrec.com
Millipore Corp	http://www.millipore.com/
Primera Analytical Solutions	http://www.primera-corp.com
Teledyne ISCO	http://www.isco.com
Thermo Fisher Scientific	http://www.thermofisher.com
XenoBiotic Laboratories	http://www.xbl.com/aboutUs/aboutUs.shtml
Yamazen	http://www.yamazenc.co.jp



Symposium Logistic Contacts

Programs	Duxi Zhang, Sunny Wang, Longqin Hu
Vendor Show	Fanwen Zeng, Qingjie Ding, Bin Wei, Fangbiao Li
Registrations	Teng Xu, Jinquan Dong, Bin Wei, XiaoQiu Wu & Volunteers
Food/Beverage Services	Bin Wei, Wenni Li, Zhongli Gao
Photography	Teng Xu, Honghong Li
Communications	Daniel Wang



Abstracts & Speaker Biosketches

Dr. Gregory J. Szpunar, Senior Vice President of Pharmaceutical Sciences and Drug Metabolism of Schering-Plough Research Institute

“Big Pharma - Where is It All Going?”

Abstract

Economic and social pressures are driving a fundamental change in the way Health Care will be delivered in the 21st century. The pharmaceutical industry is seeking to adapt to this change with a variety of strategies, often divergent. Are the days of “Big Pharma” numbered? Is the longstanding model of a large internally focused research organization coming to an end? Stayed tuned – the experiment is underway.

Bio

Gregory J. Szpunar, R.Ph., Ph.D., is senior vice president, Pharmaceutical Sciences and Drug Metabolism, Schering-Plough Research Institute.

Within Schering-Plough, Greg leads formulation development, chemical and biological process development, clinical supplies manufacture/logistics and the transfer of all processes to global operations. His area also oversees drug metabolism studies that characterize the way drugs are absorbed, broken down and eliminated from the body.

Before joining Schering-Plough, Greg was Chief Scientific Officer and senior vice president for R&D/Manufacturing at Biovail Corporation. He began his pharmaceutical career at The Upjohn Company where he held leadership positions overseeing pharmacokinetic and biopharmaceutic research. He was named vice president Worldwide Drug Metabolism when the organization became Pharmacia & Upjohn, and later was senior vice president, Product Development, for Pharmacia Corporation.

Greg earned a B.S. degree in pharmacy in 1980 from Wayne State University, where he graduated with high distinction. In 1984, he received a Ph.D. degree in pharmaceutics from the University of Michigan.



Dr. Arthur T. Andrews, Vice President of Global Drug Product Development of Johnson & Johnson Pharmaceutical R&D

“Pharmaceutical Development: Understanding Major Industry Changes in How to “Design, Develop, and Deliver” New Drugs”

Abstract

The pharmaceutical industry is undergoing a significant re-examination of its overall business model, from discovery through commercialization. As other industries have done over the past 15 years (e.g. telecommunications, computer, and electronics), pharma is looking at opening up the old business model to take advantage of new external product ideas, leaner development paradigms, and new approaches for manufacturing and marketing. Major pharma has long taken a “vertically integrated” approach toward designing, developing and delivering their drugs, but that value-chain model is being dis-aggregated to take advantage of flexible and novel external research collaborations, outsourcing of key development activities, and new models for shared development funding and commercial marketing.

This presentation will provide a view of how the value chain for pharmaceutical development of a new drug product is being changed over the industry to take advantage of internal and external innovation, outsourcing, and unique collaborative models with other major pharma companies.

Bio

Arthur T. Andrews is currently Vice President of Global Drug Product Development (DPD) Johnson & Johnson Pharmaceutical R&D. The DPD group, with bases in Raritan, Spring House, and Beerse, is responsible for supporting early and late phase pre-formulation studies, formulation design and development, analytical development, clinical drug product manufacture, and technology transfer to manufacturing. Prior to joining J&J in early 2005, Art was employed in the Merck Research Laboratories (MRL) Division of Merck and Co., Inc. There he was responsible for developing and implementing outsourcing strategies in the areas of preclinical safety toxicology, metabolism, drug supply, and formulation development. Art’s prior roles at Merck included Vice President of MRL Global Operations and Strategic Research Planning and Vice President of MRL Process R & D. Art spent the first 25 years of his career in the Process R&D area, which was responsible for the chemical process development activities for new drugs at Merck, from lab scale through piloting and eventual transfer to the manufacturing scale.

Art obtained his undergraduate degree in chemical engineering from Manhattan College, his MS degree from the California Institute of Technology and his PhD from Rutgers University, also in chemical engineering.



Dr. Paul Juniewicz, Vice President & Global Head for Access to External Innovation, sanofi-aventis
“Changing Paradigms in Pharmaceutical R&D”

Abstract

Current estimates for the discovery, development and registration of new molecules range from \$800M-1B over a period of 8-10 years. In addition, the current model of blockbuster or mega-blockbuster medicines with annual sales >\$1B in which patients pay for therapy independent of effectiveness is rapidly moving towards a more personalized medicine approach with payors/ health reimbursement agencies requiring pricing based on pay for performance. These economic changes will require changes in the current model of pharmaceutical drug discovery and development including diversification of therapeutic focus and healthcare approaches and greater focus on external alliances / collaborations particularly in the drug discovery and biomarker /diagnostic areas. In addition, future focus moving towards personalized medicines and medicines outside the traditional paradigm of small molecule pharmaceutical agents as well as biologics require creation of unique technologies (ie , autologous vaccines, stem cells) that will require greater focus on external alliance / collaborations. This presentation will provide several examples of the changing paradigms in pharmaceutical R+D and what new opportunities as well as challenges are brought by this changing paradigm.

Bio

Dr. Paul E. Juniewicz (Paul) graduated with honors from Rutgers University in 1976 (BS) and then attended graduate school at North Carolina State University (1976-1982) obtaining both MS and PhD. After a brief period with the USDA, Paul pursued post-doctoral studies in steroid biochemistry at Johns Hopkins University from 1984-1987. Subsequently, Paul joined Sterling Winthrop as a Senior Biologist in the Departments of Pharmacology and then Oncopharmacology. Following the acquisition of Sterling by Sanofi (now sanofi-aventis), Paul moved to Project Management role for Oncology projects working on such projects as oxaliplatin, Rasburicase, tirapazamine and mitoguazone. Recently, Paul moved to a new formed department within sanofi-aventis as the Global Head of Access to External Innovation.

Paul is a long-standing member of AACR and ASCO and previously was a member of DIA, AAAS and AUA. Paul has over 50 publications and several patents and was involved in the international approvals for both Oxaliplatin (Eloxatin) and Elitek/Fasturtec (Rasburicase). Paul has served on many internal senior management committees as well as been involved in collaborations including partners: Regeneron, Debiopharm, SRI, IDD, NCI, among others.



Dr. Nilesh Shah, R & D Director, Household and Personal Care, Dow Advanced Materials
“Provide Solutions in a Hyper-Competitive Marketplace”

Abstract

We are increasingly confronted with a world that is changing at an exponential pace. The evolving marketplace and the nature of competition are two components of change that directly affect scientists in the chemical industry. It is no longer adequate to bring forward inventions that offer new benefits. Instead, success lies in bringing complete solutions to customers' problems. These solutions often go beyond individual ingredients and are adopted only when they enable the customer to profitably deliver something new to the next step in the value chain. This presentation will explore the changing nature of the marketplace and competition and address ways in which research organizations are operating in this environment.

Bio

Nilesh Shah is the R&D Director for the Home and Personal Care business of the Dow Chemical Company.

Dr. Shah joined Rohm and Haas Company in 1985, starting as a Research Scientist in the Plastics business. Thereafter, he held positions of increasing responsibility in research management, leading Polymer Synthesis and Exploratory Research.

From 1999 to 2002, Dr. Shah held commercial roles in the Architectural and Functional Coatings business, with responsibility for Strategic Planning and Marketing before returning to Research in 2003 to become a Global Technology Director. In this role he led Research and Regulatory Affairs for the Consumer and Industrial Specialties business followed by the Process Chemicals and Biocides business. He transitioned to his new role after The Dow Chemical Company acquired Rohm and Haas in April of this year.

Dr. Shah graduated with his B.S. in Chemical Engineering in 1979 from Jadavpur University in Calcutta, India. He received his Ph.D. in Chemical Engineering from the University of Massachusetts at Amherst. He is a member of the American Chemical Society.



Dr. Yuguang Wang, Senior Vice President, Integrated Services and Library Generation, ChemPartner

“Life in a CRO”

Abstract

With pharma industrial consolidation, one of the career movements could be working at a CRO company. ChemPartner is one of the leading CROs with more than 1800 employees and 80 “sea turtles”. It provided not only excellent services to its customers, but also a different career opportunity to those who want something different. This talk will focus on the discussion of ChemPartner for its service, people, and culture.

Bio

Dr. Yuguang Wang is currently the Senior Vice President of Integrated Services and Library Generation at ChemPartner. Before ChemPartner, Dr. Wang was an Associate Director of Discovery Chemistry at Schering-Plough. Dr. Wang was at Schering-Plough for 19 years.

From 1990 to 2004, he worked at the drug discovery projects. He was the key inventor for three clinical candidates, a muscurinic receptor antagonist (Phase I), a PDE 5 inhibitor (Phase II) and a thrombin receptor antagonist (Phase III). He was awarded with three Schering-Plough’s Discovery President Awards, one Schering-Plough’s Impact Award and one Schering-Plough’s Special Recognition Award. He was also recognized by the research community outside Schering-Plough. He was the winner of 2008 Thomas Edison Patent Award by New Jersey Research and Development Council.

From 2004 to 2009, Dr. Wang oversaw the library generation project at Schering-Plough. He assembled a library project team to manage library production with more than 100 FTEs outside US. His team exceeded the company goal every year during the past four years.

Dr. Wang has about 50 publications and patents.



Dr. Guang Cao, Advanced Research Associate, ExxonMobile Research & Engineering Company

"Identifying and Knocking Down Barriers - An Introduction to the Diversity Partnership Program of the ACS"

Abstract

Different racial and ethnic groups face different issues in career advancement and professional fulfillment. What are the issues facing Asian American Chemical Professionals? While the level of representation in our profession by Asian Americans is not at issue, there appears to be under-representation in the governance structure. Is there an issue here? How can be more certain about it? If it is an issue, how do we go about resolving it? The ACS's Diversity Partner Program needs your help for answers.

Bio

Guang Cao is currently an Advanced Research Associate with ExxonMobil Research and Engineering Company. He received his BS degree from Jilin University in Changchun, China, and Ph.D. degree from the University of Texas at Austin. Guang served as the president of the Tri-State (New Jersey, New York, and Pennsylvania) Chinese American Chemical Society in 2006. He is a member of the ACS International Activities Committee and a voting member on the US National Committee for the International Union of Pure and Applied Chemistry. He was the initiator and chief organizer for the 1st Beijing International Chemical and Pharmaceutical Intellectual Property Forum that was held in Beijing.



Dr. Zhe-ming Gu, Vice President Biotransformation & Drug Metabolism, XenoBiotic Laboratories, Inc.

“Drug Metabolism in Drug Discovery and Development—Opportunities for CROs in China”

Abstract

Drug Metabolism information is critical in all phases of a fully integrated drug development program. The rapid profiling and identification of *in-vitro* and *in-vivo* metabolites plays an important role in drug discovery and development process, but remains very challenging. Successful metabolite profiling and identification strategies must keep pace with evolving demands for sensitivity, chromatographic resolution, robustness, diverse metabolite properties, high-throughput work flow and safety, and regulatory review. Any of these can be hurdles in the research and development landscape. Liquid chromatography coupled with mass spectrometry is a proven technique for the rapid characterization of drug metabolites from biological fluids, but often this technique does not identify the exact position of the oxidation, does not differentiate between isomeric structures and often does not provide accurate quantitative information of metabolite levels. We have utilized multiple approaches such as NMR, wet chemistry and H/D exchange techniques, coupled with mass spectrometry with accurate mass defect filtering to fully characterize the metabolites of drug candidates. The latest metabolite profiling, identification, and quantitation technologies and their implementation in our laboratories will be presented.

In the past decade, pharmaceutical companies have outsourced more and more discovery chemistry services, including lead generation, lead optimization, and synthetic chemistry, etc., to China. Eyeing on the success of the auto-industry in China, most large pharmaceutical companies have set up labs in China now. Some leading pharmaceutical companies have established their own R&D centers in China with a-to-z drug discovery and development programs. Thus, increasing demands for services in China can be easily foreseen. XBL has set up a branch (XBL-China) in China, with an office in Zhangjiang High-Tech Park in Shanghai, and laboratories in Nanjing, Jiangsu province. Our initial business will focus on *in vitro* and *in vivo* ADME and bioanalysis services, similar to our core business in the US, but, in the near future, XBL-China will expand to cover services for pharmaceutical analyses and development of biologics.

Bio

Dr. Gu is the Vice President of Biotransformations and Drug Metabolism at XenoBiotic Laboratories, Inc. (XBL). He manages and directs drug metabolism and bioanalysis of all types of molecules from drug discovery to development. To complete his tasks at XBL, he leads his team utilizing various HPLC/radio-chromatography, LC/MS/MS, and NMR instruments. Dr. Gu received his Bachelor's degree in Pharmacy in 1982, and obtained his Ph.D. in Pharmacognosy from Beijing Medical University in 1986. From 1989.1.-1990.1, Dr. Gu obtained World Health Organization (WHO) scholarship and worked as visiting researcher at Toyama Medical and Pharmaceutical University, Japan, for a year. He was promoted to a full professor in China in 1992. He then went to USA and pursued his research (as the head post-doctor) in Natural Product Chemistry at Purdue University for three years. He joined XBL and has worked there for almost 15 years in drug metabolism and bioanalysis fields. He has published over 70 articles or book chapters in various scientific fields.



Dr. Hong Xu, Vice President of Business Development, Medicilon Inc.

"Creating innovative models of partnering with China to enrich pharmaceutical product pipelines"

Abstract

Bio

Dr. Xu has 15 years experience at Pfizer in both research and business development. She was responsible for identifying novel disease targets, assay development that led to two research collaborations. During her tenure with Pfizer business development, Dr. Xu led multiple licensing teams in cardiovascular, diabetes, bone disorders, oncology, infectious diseases and gastrointestinal therapy areas that completed several licensing and acquisitions deals. Dr. Xu holds Ph.D in Molecular Biology from Albert Einstein College of Medicine, and then became a postdoctoral research fellow at Harvard Medical School studying molecular immunology. Dr. Xu received her M.D. from Beijing University Medical School. Dr. Xu also conducts consulting on biotech and pharmaceutical business through WE BioSciences.



Matt Giovine, Senior Director of Business Development, AstaTech Inc.

“Technology Licensing Opportunity for small CRO Companies”

Abstract

Bio



Dr. Chen Peng, Director of Business Development, US and China, Mestrelab Research SL

“From Chemistry to NMR Software Development to Business Development: My Experiences”

Abstract

Chen Peng started as an organometallic chemistry in Wuhan University and entered Shanghai Institute of Organic Chemistry for graduate studies. His strong interest in computer software drove him to pursue his thesis work in computer programming for automated structure determination using 1D and 2D NMR data. Later he spent nearly 20 years researching and developing NMR related software tools for chemists and biochemists in several labs and companies. Lately his active participation in marketing and technical support led him to switch to business development for Mestrelab Research, a Spain-based company that develops software for processing, analysis, and reporting NMR and LC/GC/MS for chemical and pharmaceutical applications. His territories include both US and China. He considers his move from R&D to business development a challenging yet rewarding change. In this talk he shares his experiences with such a career change, and the challenges and excitements in his new job.

Bio

Chen Peng got his BS in organometallic chemistry from Wuhan University in 1987, and got his PhD from the Shanghai Institute of Organic Chemistry in 1993. His thesis work was on the research and development of software tools for computer-assisted structure elucidation using 1D and 2D NMR data. He did postdoctoral research work in the National High Magnetic Field Laboratory in Tallahassee FL between 1994-1996. His first industrial job was in a startup company, Spectrum Research LLC, in Madison WI, where he worked as a software developer for NMR-SAMS, the commercialized software based on his PhD work. Later he worked as a senior software developer on Felix, a software package for biomolecular NMR analysis, in MSI/Accelrys between '98 and '03. Between '04 and '08, he worked as a senior software developer and product manager on KnowItAll, a software package for spectral data management and analysis and NMR-based metabolomics. In early 2008, Chen changed his career from software development to business development, and joined Mestrelab Research as a director of business development for MestreNova NMR and MS software for both US & China.



Charles Ye, President & Founder, Acesys PharmaTech

“Acesys Approach to One-stop CRO Service-Drug Discovery Platform at China Medical City”

Abstract

Acesys Pharmatech is a Chemistry based CRO company founded in 2004, providing medicinal chemistry service to pharmaceutical companies around the world. China Medical City (CMC) is the biggest agglomeration planning of medicine in China. With tremendous support from central and local government, CMC is strived to become the No. 1 center in China. Acesys is working with CMC to build a research platform for pharmaceutical research, including Medicinal Chemistry, Biology screening, cGMP process, cGMP formulation, and service support center, etc. These platform will be managed by experienced returnees and open to everyone.

Bio

Charles Ye worked at Schering Plough Research Institute in New Jersey as medicinal chemist and research finance analyst from 1998 to 2004 before he founded Acesys Pharmatech in 2004 in Nanjing China. He also serves as the Associate Director of Nanjing Association for Overseas Chinese Scholars (NAOCS). He organized several international meetings and local meetings in pharmaceutical area in Nanjing.



Tri-State CACS Officers (2009)

President	<i>Sunny Xuhong Wang</i> Sunny.Wang@Sanofi-aventis.com
President-Elect	<i>Duxi Zhang</i> duxizhang@yahoo.com
Immediate Past-President	<i>Longqin Hu</i> LongHu@rutgers.edu
Treasurer	<i>Xiaoqiu Wu</i> xiaoqiuwu@yahoo.com

Board of Directors

*Ding, Qingjie; Dong, Jinquan; Gao, Zhongli; Huang, Yong; Li, Fangbiao; Li, Wenni;
Tong, Quinn; Wang, Sunny Xuhong; Wang, Yanong; Wei, Bin; Wu, Xiaoqiu; Xu, Teng;
Zeng, Fanwen; Zhang, Duxi; Zhong, Wendy*

Advisory Board

*Cao, Guang; Cao, Ping; Chang, David Y.; Chen, Chien-Kuang; Chen, Guodong; Chen, K.
Y.; Chen, Meng-Hsin; Chen, Shaoqing; Cheung, Hong-Son; Chiang, Joseph; Dub, How-
Yunn; Guo, Paul; Ho, Teh C.; Hsieh, Tony Y.; Hu, Kevin; Hu, Longqin; Lan, Shih-Jung;
Li, Ge; Ma, Wuping; Qian, Kuangnan; Shi, Shawn; Shih, Neng-Yang; Sien, Ernest; Su,
Heng; Sun, Yongkui; Tan, Hock; Wang, Stephen; Wang, Yuguang; Xia, Tianhui; Yeh,
Lisa; Zhang, Donglu; Zhang, Hongjian; Zhang, Xumu*